On October 19, 2015, Neos Therapeutics released that the U.S. Food and Drug Administration had found insufficiencies in its new drug application for Cotempla XR-ODT that impede the labeling and marketing requirements at this time. Neos Therapeutics stock dropped over 23% during intraday trading on October 20, 2015. On August 11, 2016, Neos Therapeutics released its financial results for the second quarter of 2016, recording it had missed its projections by $0.49 per share. Following this news, Neos Therapeutics stock dropped from a close of $8.57 per share on August 10, 2016 to a close of $7.27 per share on August 11, 2016.
If you are aware of any facts relating to this investigation, or purchased shares of Neos Therapeutics, you can assist this investigation by visiting the firm's site: http://www.bgandg.com/neos. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484 or via email firstname.lastname@example.org. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | email@example.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-neos-therapeutics-inc-neos-300329959.html
SOURCE Bronstein, Gewirtz & Grossman, LLC